Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

What are the best ASX shares for dividend investing? They all belong to these 4 sectors

What are the best ASX shares for dividend investing? It is difficult to pick individual stocks because dividends can fluctuate from year to year. However, the best ASX shares for dividend investing tend to come from four specific sectors: financials, resources, healthcare and utilities and they tend to be the largest companies…

ByNick SundichJuly 1, 2025

Here’s why it is a terrific time to look at ASX biotech small caps, and 4 worth considering for FY26

It's been a tough few years for ASX biotech small caps. Even in the last 18 months, the market recovered from post-COVID inflation small cap biotechs have been left behind. The ASX 200 Healthcare Index is down 7% in 2025 whilst the broader ASX 200 is up 4% (yes, even with the crash due to…

ByNick SundichJuly 1, 2025

Clarity Pharmaceuticals (ASX:CU6) is off all time highs but is a $600m company! Is it the next Telix?

When we last wrote about Clarity Pharmaceuticals (ASX:CU6), in July last year, it was a multi-billion dollar company, less than 3 years after an IPO that valued the company at $350m. In retrospect, that was kind of a kiss of death because it retreated back to $700m. So where to next for the company? Is it…

ByNick SundichJune 26, 2025

AFT Pharmaceuticals (ASX:AFP): A gem of a dual-listed healthcare company

AFT Pharmaceuticals (ASX:AFP) may not spring to mind as the best company to have come out of New Zealand. Many investors would say that title belongs to Xero (ASX:XRO). Nonetheless, however much AFT Pharmaceuticals has slipped under the radar, it deserves a lot more attention than it has received from investors, given its progress since…

ByNick SundichJune 24, 2025

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

Israel’s strikes on Iran, and the subsequent responses, led to the typical "risk off" moves professional investors usually make when faced with uncertainty. But what exactly does "risk off" mean and how relevant is it for retail investors? Should you be risk off too or should you ride out geopolitical uncertainty? Few would've predicted Israel would've…

ByNick SundichJune 18, 2025

Monash IVF (ASX:MVF): Just when you thought a difficult 5 year span was over…

In the decade since fertility provider Monash IVF (ASX:MVF) listed, it was not an easy journey. Only a few months ago, we thought the business had turned a corner and many others did too. Then...trouble struck. Is this a buy the dip opportunity, or a risk of catching a falling knife? Introduction to Monash IVF Monash…

ByNick SundichJune 10, 2025

How to stop the ASX decline? ASIC and investors have some radical ideas

Addressing the ASX decline is a question that has been considered for many months now. In 2023-24, more companies left the ASX in the past 2 years than any 2 year period since the 1990s recession - whether being brought out by private equity or a big industry player, delisting to a penny stock exchange…

ByNick SundichJune 6, 2025

Here’s why investors in health insurance stocks like Medibank and NIB should stay alert

Health insurance stocks are facing a big dilemma right now. On one hand patients don't want to pay more, but private hospitals want them to pay more. What's new about that, you might ask? Well, the collapse of Healthscope has bought this issue to the forefront, and something will have to give sooner or later. Of…

ByNick SundichJune 5, 2025

Investing in IPOs (Initial Public Offerings) in 2025: Here’s what investors need to know

Investing in IPOs offers the opportunity for investors to make gains they couldn't make with any other company, but also offer a risk of making significant losses which you may not be able to recoup. They're also a major milestone for companies involved, as they not only provide access to significant amounts of capital but…

ByNick SundichJune 3, 2025

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

2025 has been, and will continue to be, a big year for Proteomics, which has just launched PromarkerD onto the Australian market. Before this year is over, the company anticipates launching another 2 tests - PromarkerEndo and PromarkerEso; and is eyeing off the US market too. Recap of Proteomics (ASX:PIQ) For investors that are new to…

ByNick SundichMay 28, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

What are the best ASX shares for dividend investing? They all belong to these 4 sectors

Here’s why it is a terrific time to look at ASX biotech small caps, and 4 worth considering for FY26

Clarity Pharmaceuticals (ASX:CU6) is off all time highs but is a $600m company! Is it the next Telix?

AFT Pharmaceuticals (ASX:AFP): A gem of a dual-listed healthcare company

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

Monash IVF (ASX:MVF): Just when you thought a difficult 5 year span was over…

How to stop the ASX decline? ASIC and investors have some radical ideas

Here’s why investors in health insurance stocks like Medibank and NIB should stay alert

Investing in IPOs (Initial Public Offerings) in 2025: Here’s what investors need to know

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here